Vivos Therapeutics announced that it has entered into definitive securities purchase agreements with institutional investors for the issuance and sale of an aggregate of 1,363,812 shares of its common stock at a purchase price of $3.15 per share in a registered direct offering priced at-the-market under the rules of the Nasdaq Stock Market. No common stock purchase warrants are being issued in this offering. The closing of the offering is expected to occur on or about September 20, 2024, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VVOS:
- Morning Movers: General Mills dips following Q2 report
- Vivos receives FDA 510k clearance to treat pediatric sleep apnea, snoring
- Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring
- Vivos Therapeutics Enhances Incentives and Executive Pay Structure
- Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue